Work

Gastrointestinal hypomotility and dysmotility reporting with GLP-1 receptor agonists and tirzepatide: a FAERS study of drug-specific patterns and onset

Year: 2026
Type: article
Study design: Observational Study
Abstract: Glucagon-like peptide-1 receptor agonists and tirzepatide affect gastrointestinal motility, but drug-specific reporting and onset of events beyond common symptoms remain incompletely characterized. We examined these events to inform clinical assessment. We analyzed deduplicated FDA Adverse Event Reporting System reports from 2021Q1 to 2026Q1 in which one of six target drugs was designated the primary suspect. Study-defined preferred terms were grouped as core hypomotility/dysmotility events, supportive gastrointestinal symptoms, or exploratory aspiration-related events. We assessed reporting disproportionality, drug-specific patterns, serious outcomes, reporting-source sensitivity, and time to onset using treatment dates matched to the target drug. Among 243,269 target-drug reports, 6,252 involved core events. Core reporting was disproportionate (reporting odds ratio, 7.02; 95% confidence interval, 6.83–7.22), including reports of impaired gastric emptying, hypomotility, ileus, and intestinal obstruction. Four of six therapies showed positive core-group ROR signals, with drug-specific patterns across impaired gastric emptying, hypomotility, ileus, and obstruction. Serious outcomes were recorded in 91.3% of core reports. Among reports with valid target-drug-matched dates, median reported onset was 71.5 days for core events ( n = 1,986) and 2 days for supportive symptoms ( n = 8,335). Of 189 aspiration-related reports, 97 also contained core or supportive gastrointestinal terms; no positive aggregate aspiration signal was detected. Excluding lawyer-submitted reports reduced the 2026Q1 core reporting proportion, particularly for dulaglutide. Gastrointestinal motility-related reporting encompassed impaired gastric emptying, hypomotility, ileus, and obstruction, with variation across drugs and in recorded onset intervals. These findings highlight presentations that warrant clinical assessment during treatment and guide focused evaluation in clinical data.
Language: English
Subfield: Toxicology
Open Access status: gold
Estimated APC paid: $3,190
OpenAlex ID: W7233742553
FWCI:
Cites:
Cited by:
Related to: 10